| Title |
Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
|---|---|
| Published in |
PharmacoEconomics, December 2019
|
| DOI | 10.1007/s40273-019-00870-w |
| Pubmed ID | |
| Authors |
Willem J. A. Witlox, Antoinette D. I. van Asselt, Robert Wolff, Nigel Armstrong, Gill Worthy, Annette Chalker, Titas Buksnys, Lisa Stirk, Jos Kleijnen, Manuela A. Joore, Sabine E. Grimm |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 43 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 14% |
| Student > Postgraduate | 4 | 9% |
| Student > Doctoral Student | 4 | 9% |
| Other | 3 | 7% |
| Researcher | 3 | 7% |
| Other | 6 | 14% |
| Unknown | 17 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
| Unspecified | 1 | 2% |
| Arts and Humanities | 1 | 2% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 18 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 December 2019.
All research outputs
#14,466,797
of 23,179,757 outputs
Outputs from PharmacoEconomics
#1,474
of 1,867 outputs
Outputs of similar age
#246,213
of 459,116 outputs
Outputs of similar age from PharmacoEconomics
#24
of 32 outputs
Altmetric has tracked 23,179,757 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,867 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 459,116 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.